GleamWall
中文EN

ROIV Roivant Sciences Ltd.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1635088 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY102.1%
TTM net income YoY7.9%
TTM EPS YoY-5.5%
Revenue 3-yr CAGR-16.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,358.1%
Net margin-838.2%
FCF margin-81.2%
EBITDA margin-1,352.0%

Returns

ROE-8.2%
ROA-6.9%
ROIC (approx.)-16.0%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets7.6%
Debt / equity0.00x
Current ratio15.56x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.11x
Accruals ratio-6.1%
Payout ratio—
Capex / revenue-7.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252026-03-31FY20242025-03-31
Income statement
Revenue$8.26M$29.05M
R&D expense$681.81M$550.41M
SG&A expense$610.47M$591.41M
Operating income-$515.07M-$1.00B
Pretax income-$264.58M-$681.59M
Income tax$133.33M$48.17M
Net income-$299.77M-$171.98M
EBITDA-$511.72M-$989.22M
EPS (basic)-0.43-0.24
EPS (diluted)-0.54-0.24
Weighted avg. shares (diluted)693.86M725.40M
Balance sheet
Cash & equivalents$1.42B$2.72B
Short-term investments$2.87B$2.17B
Current assets$5.17B$5.00B
PP&E, net$11.99M$12.06M
Total assets$5.71B$5.44B
Current liabilities$281.24M$149.41M
Total liabilities$416.27M$249.74M
Shareholders' equity$4.53B$4.69B
Shares outstanding720.35M695.94M
Cash flow statement
Operating cash flow-$750.35M-$839.45M
Capital expenditure$8.21M$4.60M
Free cash flow-$758.56M-$844.05M
Investing cash flow-$682.33M-$1.77B
Financing cash flow$134.24M-$1.22B
Depreciation & amortization$3.35M$14.07M
Stock-based compensation$346.17M$289.03M
Share buybacks—$1.29B

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.